Volume 145, Issue 11 pp. 3152-3162
Tumor Markers and Signatures

Identification of prognostic molecular biomarkers in 157 HPV-positive and HPV-negative squamous cell carcinomas of the oropharynx

Snjezana Dogan

Corresponding Author

Snjezana Dogan

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

S.D. and B.X. contributed equally to this workCorrespondence to: Snjezana Dogan, MD, Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA, Tel.: +1-212-639-4878, E-mail: [email protected]; or Ian Ganly MD, MSc, PhD, Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA, Tel.: +1-212-639-6244, E-mail: [email protected]Search for more papers by this author
Bin Xu

Bin Xu

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

S.D. and B.X. contributed equally to this workSearch for more papers by this author
Sumit Middha

Sumit Middha

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

Search for more papers by this author
Chad M. Vanderbilt

Chad M. Vanderbilt

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

Search for more papers by this author
Anita S. Bowman

Anita S. Bowman

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

Search for more papers by this author
Jocelyn Migliacci

Jocelyn Migliacci

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

Search for more papers by this author
Luc G.T. Morris

Luc G.T. Morris

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY

Search for more papers by this author
Venkatraman E. Seshan

Venkatraman E. Seshan

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY

Search for more papers by this author
Ian Ganly

Corresponding Author

Ian Ganly

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY

Correspondence to: Snjezana Dogan, MD, Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA, Tel.: +1-212-639-4878, E-mail: [email protected]; or Ian Ganly MD, MSc, PhD, Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA, Tel.: +1-212-639-6244, E-mail: [email protected]Search for more papers by this author
First published: 16 May 2019
Citations: 41
Conflict of interest: The authors declare no potential conflicts of interest.

Abstract

The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been increasing due to high-risk HPV infection. We explored the significance of genetic alterations in HPV-positive (HPV-P) and HPV-negative (HPV-N) OPSCC patients on long-term outcome. A total of 157 cases of primary resected OPSCC diagnosed from 1978 to 2005 were subjected to a targeted exome sequencing by MSK-IMPACT™ interrogating somatic mutations in 410 cancer-related genes. Mutational profiles were correlated to recurrence and survival outcomes. OPSCC included 47% HPV-positive (HPV-P) and 53% HPV-negative (HPV-N) tumors arising in the base of tongue (BOT, 43%), palatine tonsil (30%) and soft palate (SP, 27%). HPV negative status, SP location and smoking were associated with poorer outcome. Poorer overall survival was found in NOTCH1-mutated HPV-P (p = 0.039), and in SOX2-amplified HPV-N cases (p = 0.036). Chromosomal arm gains in 8p and 8q, and 16q loss were more common in HPV-P (p = 0.005, 0.04 and 0.01, respectively), while 9p, 18q and 21q losses were more frequent in HPV-N OPSCC (p = 0.006, 0.002 and 0.01, respectively). Novel, potentially functional JAK3, MYC and EP300 intragenic deletions were found in HPV-P, and FOXP1, CDKN2A, CCND1 and RUNX1 intragenic deletions and one FGFR3 inversion were detected in HPV-N tumors. HPV-N/TP53-wild-type OPSCC harbored recurrent mutations in NOTCH1/3/4 (39%), PIK3CA, FAT1 and TERT. In comparison to their oral and laryngeal counterparts, HPV-N OPSCC were genetically distinct. In OPSCC, HPV status, tumor subsite and smoking determine outcome. Risk-stratification can be further refined based on the mutational signature, namely, NOTCH1 and SOX2 mutation status.

Abstract

What's new?

For oropharyngeal squamous cell carcinoma (OPSCC), HPV status and mutational profile may affect prognosis. In this study, the authors found that certain mutations, including NOTCH1 mutations in HPV-positive OPSCC and SOX2 amplification in HPV-negative OPSCC, are associated with poor prognosis. These results indicate that sub-stratification of OPSCCs based on mutational signatures may help to predict outcomes and aid treatment planning. Data from various subsites (oropharynx, larynx and oral cavity) also suggest that HPV-negative OPSCC is a genetically heterogeneous disease.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.